A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells.
Varghese Palath(Sunesis (United States)), Christopher Bebbington(Curtin University), Andreia Lee(Sunesis (United States)), Alan F. List(TE Laboratories (Ireland)), Andrew M. Scott(Olivia Newton-John Cancer Wellness & Research Centre), J.C. Williams(Allakos (United States)), Rohini Vekhande, Andy Boyd(The University of Texas at San Antonio Health Science Center), Ling Zhang(Hebei Medical University), Geoffrey Yarranton, Martin Lackmann(Monash University), Daniela Cilloni(University of Turin)
Cited by 3
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Efficacy of Lenalidomide in Myelodysplastic Syndromes
|New England Journal of Medicine|2005|874
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product
|The Journal of Immunology|1998|546